Understanding the Gene Therapy Market Today
|
|
- Betty Andrews
- 6 years ago
- Views:
Transcription
1 Understanding the Gene Therapy Market Today February 2017 Author: Richard Tinsley, Strategy Partner C International
2 Contents A Case Study Utilizing Gene Therapy to Correct Genetic Vision Problem 1 Learning from History 2 Classifying Gene-Based Technology 3 Gene-Based Therapeutic Technologies 5 Building Better Vehicles 6 Elements of Success 7 First Mover Advantage 7 Public Private Partnerships 7 The Road Ahead 9 Value Proposition 9 Market Size 9 Commercialization 9 Access/Adoption 10 Capital Funding 10
3 A Case Study Utilizing Gene Therapy to Correct Genetic Vision Problem Siblings Caroline and Cole Carper had slowly been going blind since birth. Both children were born with a rare genetic disease that causes defects the retina, the part of the eye that detects lights and color. The siblings had to learn to read braille and were attending a school for the blind before they enrolled in a gene therapy clinical trial. The experimental treatment, developed by Spark Therapeutics, Philadelphia, PA., would change their lives. Two years after the children received retinal injections of modified viruses carrying genes designed to correct their genetic defect, their vision had improved markedly. But the treatment that preserved the vision of two small children who would otherwise almost certainly have gone blind also marks a larger milestone for the nascent field of gene therapy. The experimental treatment of 31 patients was the first successful randomized, controlled Phase III trial ever completed in gene therapy. The company plans an imminent FDA Biologics License Application (BLA). If approved, it could become the first of an eventual cavalcade of gene-based therapies approved for sale in the US. Spark is one of several companies developing gene-based treatment for vision loss in the US and Europe. RetroSense Therapeutics, a subsidiary of Allergan based in Ann Arbor, MI., is focused on gene-based therapy to restore vision in patients with retinitis pigmentosa and advanced dry age-related macular degeneration. Their proprietary technology, now in Phase I/II clinical trials, uses optogenetics, which aims to restore light sensitivity to damaged cells in the retina. As the number of gene therapy clinical trials reporting positive results increases, it s becoming clear that gene therapy is moving toward commercialization. Now a part of the portfolio mix for many of the biggest companies in the biopharmaceutical arena, gene therapy is suddenly a hot investment sector. The focused gene therapy sector including companies like Spark now has a cumulative market cap in the neighborhood of $10 billion dollars. As companies seek to commercialize gene-based therapies, it is instructive to remember that gene therapy has not followed a linear trajectory, nor will its commercial pathway be straightforward either. 1
4 Learning from History Gene therapy appeared destined for great things in the early 1990s, with more than 100 gene-based clinical trials planned or underway in 1999, before the tragic death of a clinical trial participant cast a pall on the entire nascent gene therapy industry. Jesse Gelsinger s death mere days after receiving an injection meant to correct an inherited liver condition forced a reevaluation of the technology s safety. The corrective gene given to Mr. Gelsinger was not the problem instead the delivery vehicle, a version of the common cold virus, triggered a massive reaction in his immune system that overwhelmed his body and led ultimately to brain death. Since these heady early days, gene-based therapy has developed along a more deliberate path. There have been marked improvements in vectors and techniques that show none of the devastating side effects seen in earlier years. Finally, gene-based therapies seem poised to deliver on their early promise. Nonetheless, it s important to remember that the vast majority of gene therapy-based treatments are in the very early phases of clinical development, with only a few in late stage trials. Phases of Gene Therapy Clinical Trials (July 2015) 1283 Phase I Phase I/II Phase II Phase II/III Phase III Phase IV Source: Journal of Gene Medicine, 2015; Gene Therapy Market, , RxC Research 2
5 Classifying Gene-Based Technology Definitions of what constitutes gene therapy vary, and even federal science and regulatory agencies can t agree on a common definition. People often use the terms cutting and pasting genes borrowed from word processing terminology to visualize gene therapy. This simplistic characterization can lead to the misunderstanding that gene therapy involves cutting out a defective or malfunctioning gene and inserting a new, functional copy in its place. Today, gene-based therapy comprises a range of applications and tools that provide much more precise control than earlier technology. New gene manipulation tools have proliferated. Understanding the differences between technologies is essential to accurately evaluating their potential. No biotech investor would compare a company developing a diabetes drug with one developing a surgical implant head to head because the underlying technology and potential market are not comparable. Similarly, it s important to understand how gene-based technologies differ and what position they are likely to fill within the healthcare marketplace. Some gene-base technologies may be one-shot treatments comparable to surgeries, while others will require ongoing periodic treatment. Nonetheless, the umbrella term gene therapy is often used to cover a plethora of related technologies developing in parallel. These technologies, at different stages of maturity, are not equivalent. 3
6 4 Understanding the Gene Therapy Market Today Classifications of Gene Therapy Gene Replacement Gene Silencing Gene Editing (TALEN/CRISPR) Stem Cell Delivery Diagnostics This technique may allow doctors to treat a disorder by inserting a gene into a patient s cells instead of using drugs or surgery to improve function. Researchers are testing several approaches to gene replacement therapy. For instance, a loss of gene function may cause a disease, and this loss can be replaced by adding a normal copy of the gene to a cell. A broad number of therapies are being investigated in the clinic for application in both monogenic disorders, and somatic cell diseases such as cancer. A therapy is currently on the market in Europe that replaces the lost function in disease patients of an enzyme that breaks down lipid in the body. An approach used to inhibit gene expression in a cell. Gene silencing can occur during either transcription or translation and is often used in research to test the function of a gene in a cell by using silencing RNA (sirna) and short hairpin RNA (shrna) sequences to block gene function. A number of therapies representing this approach are being tested in the clinic, and one is currently on the market in the US for treating patients with a rare cholesterol disorders. Gene editing is a potential approach to alter the human genome to treat genetic diseases, viral diseases, and cancer. While still years from being used in medicine, several exciting advances have been made. TALENs: Transcription Activator-Like Effector Nucleases are restriction enzymes that can be engineered to target, cut and modify specific sequences of DNA. CRISPR-Cas9: A recent breakthrough technology is the combination of short bar-code sequences (Clustered Regularly Interspaced Short Palindromic Repeats) with a nuclease (Cas9). Together with a guide RNA to target editing to the correct gene sequence, extremely precise changes in a gene can be achieved. Current efforts to design gene replacement therapies that can be delivered to patients include Hematopoietic Stem Cell (HSC) and induced Pluripotent Stem Cell (ipsc) approaches. HSC s are bone marrow derived progenitor cells that give rise to cells of different types. Most common therapy applications are in the areas of blood and immune system disorders. ipsc s are cells that have been de-differentiated from, for example, skin cells. The ipsc can then be differentiated into a cell of a given type. Molecular Diagnostics drives the aforementioned therapeutic approaches, which aim to capitalize on newfound abilities to broadly and rapidly identify genetic defects that are disease causative. The advancement of Next-Generation Sequencing (NGS) technologies has driven down the cost of whole genome sequencing, and allows deep sequencing of targeted areas of the genome. A personalized medicine approach that identifies therapy options is gaining rapid acceptance as Centers for molecular diagnosis become widespread, and the informatics to support diagnostic analysis is developed.
7 Gene-Based Therapeutic Technologies For instance, while there is justified enthusiasm surrounding the potential of CRISPR, ZNF and TALEN technologies, these promising platforms, which fall within the broad category of gene editing, are in the early stages of development. Further, they are currently the subject of patent litigation and there are many questions of safety and efficacy in humans still to be addressed. In contrast, the two most mature technologies, gene replacement for single-gene disorders and gene silencing, in which defective genes are turned off, are both poised for near-term market entry. But while the media frequently focuses only on the rare inherited genetic defects (as in the story of Caroline and Cole Carper), the vast majority of gene-based treatments are directed toward much more common and devastating diseases, with almost two-thirds targeting cancer. Indications of Gene Therapy Clinical Trials (2015) Infectious Diseases 8% Others 11% Cardiovascular Diseases 8% Cancers 64% Monogenic Diseases 9% Source: Journal of Gene Medicine, 2015; Gene Therapy Market, , RxC Research 5
8 Building Better Vehicles If gene therapy were limited to correcting rare single gene defects, it would realize only a fraction of the potential opportunity. Many companies in the gene therapy space are developing robust delivery vehicles with the expectation that once the technology has been proved safe in a proof-of-concept with a single gene disorder, the platform can then be used to launch the company into much larger market segments, including cancer. Companies are now applying decades of research to understand what makes cancer cells different and targeting those differences. Using next-generation gene delivery vehicles, they are delivering genetic payloads that target unique features of cancer cells that normal cells lack. Oncolytic viruses are successfully targeting and destroy tumor cells. Gene therapy is being combined with immunotherapy to target cancer cells and enlist the patient s immune system to kill them. Two of three advanced chronic lymphocytic leukemia patients treated with the experimental protocol were healthy more than two years after their treatment, with the engineered cells helping keep them in remission. The reports, in 2011 and 2012, represented the first successful use of gene transfer therapy to turn the body s own immune cells into powerful agents targeting cancer cells. This and other similar successes helped fuel the current abundance of gene therapy treatments for cancer. 6
9 Elements of Success First Mover Advantage For potentially curative gene therapy being first-to-market is critical to tap unmet need, according to Sean Ainsworth, CEO of RetroSense. The first mover advantage is hugely meaningful, he says. Latecomers will find a much smaller market because the population is only new cases, which in a rare disease is a very small market. Case in point, bluebird bio, Inc., a publicly traded clinical-stage company is developing gene therapy for genetic diseases, with T cell-based immunotherapies for cancer in its pipeline. bluebird s Star beam Study, a global, multi-center study, is assessing the efficacy and safety of an investigational gene therapy in boys with cerebral adrenoleukodystrophy (CALD), also known as Lorenzo s Oil disease, a rare and fatal inherited single gene neurodegenerative disease. The Phase 2/3 study is evaluating a lentivirus vector delivering engineered bone marrow cells in which a normal copy of a gene is inserted. In addition, bluebird bio has diversified its portfolio to include applications of its vector to beta-thalassemia and sickle cell disease, as well as investing in downstream gene editing technologies. Public Private Partnerships Despite significant private capital investment, gene therapy remains at this point centered in academic medical centers, which will likely play a central role in gene therapy delivery, at least in the short-term. Public-private partnerships have been the critical catalyst to pull together alliances that advance gene therapy approaches. Properly structured pharmaceutical public-private partnerships between academic researchers and for-profit firms can stimulate innovation, spur growth, and enhance 7
10 8 Understanding the Gene Therapy Market Today value by bridging the valley of death between academic discoveries in university laboratories and the commercialization of a promising therapy. For instance, Glaxo Smith-Kline is now treating children with inherited immune system deficiency (ADA-SCID), with Strimvelis technology acquired from Ospedale San Raffaele (OSR) and Fondazione Telethon (Telethon), a big funder of gene therapy investigation in Europe. Its platform is expected to provide a launch pad for applications aimed at much more common diseases. Developing and cultivating strategic partnerships with academic medical centers likely to have the infrastructure to deliver these experimental treatments could be critical to moving treatments into clinical trials. In the realm of gene silencing, small RNA technology amenable to chemical modification of the oligonucleotide backbone provides another promising avenue for genebased treatment. This to me, says Mark Scheideler, PhD, Founder of HumanFirst Therapeutics LLC, represents a next-gen in the industry of small molecule synthesis that s been traditionally done. It s a pretty mature technology that s got a big pipeline coming along.
11 The Road Ahead Companies developing gene therapy products are entering uncharted waters in terms of intellectual property protection, regulatory climate, production, distribution, and freedom to operate. Just as the science of genetic therapy is complex and daunting, so too are the commercial issues. Any company developing a genetic therapy product needs to understand and address these critical issues: Value Proposition What is the target value proposition (TVP) of a given technology? How will you determine price? Market Size What is the potential size of the patient opportunity? Who is the competition and are you likely to be first to market? Commercialization Can your company commercialize alone or do you need a larger partner? Are you building a platform to launch a robust product pipeline? How do academic or other public partnerships create or limit the commercial opportunity? 9
12 10 Understanding the Gene Therapy Market Today Access/Adoption How will you gain access through payers? Will you pursue innovative pricing strategies? What is your distribution model and how will patients get treatment? Who will be the early adopters and what are the adoption hurdles across HCP segments? Capital Funding Who owns the intellectual property rights? Do you have freedom to operate and a clear path to market? What competing technologies or commercialization challenges affect your ability to raise capital or move forward with development and commercialization?
13 C International About RxC International: RxC International is a premier life sciences management consulting firm. RxC collaborates with clients to identify and develop growth opportunities. The firm leverages consulting partners and executives to combine strategic and operational expertise to bring multiple perspectives to every engagement. The firm has deep expertise in corporate strategy, new product planning and commercial excellence. Clients include leading pharmaceutical, biotechnology, and medical technology companies around the world. The firm also supports private equity and venture capital firms on strategic transactions. The firm s corporate headquarters is located in Morristown, New Jersey, and it has offices in Massachusetts and California. Additional information about RxC International can be found at Contacts: Info@RxCInternational.com; Richard Tinsley rtinsley@rxcinternational.com
ALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES
ALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES Novel Development Programs for Potential Treatments of Serious Ocular
More informationStem Cells: Introduction and Prospects in Regenerative Medicine.
Stem Cells: Introduction and Prospects in Regenerative Medicine www.gothamgazette.com/.../stemcell/stem_cell.jpg Ode to a Stem Cell, Part II by VCW There once was stem cell stuck in the hood Dividing endlessly,
More informationVertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis -Collaboration to explore use of mrna Therapeutics to treat the underlying cause of CF
More informationREGENXBIO Inc. Ticker: RGNX
REGENXBIO Inc. Ticker: RGNX I know what you are thinking. You are about to read another biotech report with more acronyms than words you know the definitions. I promise you this report is written in layman
More informationModerna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities
Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 26 Strategic Priorities First Phase I study underway in Europe for mrna 44; IND for second program,
More informationGene Therapy: The Basics. Mark A. Kay MD PhD Dennis Farrey Family Professor Stanford University
Gene Therapy: The Basics Mark A. Kay MD PhD Dennis Farrey Family Professor Stanford University Definition of gene therapy Gene therapy is the introduction of nucleic acids (e.g. DNA/genes) into somatic
More informationGlobal Gene Therapy Market Report -2026
Global Gene Therapy Market Report -2026 July 2018 Table of Contents 1 Executive Summary 2 Gene Therapy: Overview Viral Vectors for Gene Therapy Viral Vectors Non-Viral Vectors Types of Gene Therapy Somatic
More informationOrchard Therapeutics. Overcoming the complex challenges associated with ex vivo gene therapies. Adrien Lemoine VP Business Development & Operations
Orchard Therapeutics Overcoming the complex challenges associated with ex vivo gene therapies Adrien Lemoine VP Business Development & Operations Orchard at a glance Who we are Our mission Team Academic
More informationThe NYSCF Research Institute
Regenerative Medicine Research Update Susan L. Solomon The NYSCF Research Institute New York Pharma Forum February 25, 2016 Regenerative Medicine Research Regenerative medicine uses laboratory grown human
More informationHarvard Stem Cell Institute
Welcome to the Harvard Stem Cell Institute The 1000+ scientists in the HSCI network share one goal: finding cures for human diseases. We aim to: Stimulate healing in patients by harnessing the potential
More information-- Sarepta strengthens position as a leader in gene therapy; expands rare disease franchise --
Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies -- Sarepta
More informationDelivering on the Promise of Precision Medicine
Delivering on the Promise of Precision Medicine Bay Area Council Economic Institute Spring 2016 The Promise of Precision Medicine The Bay Area is one of the world s biggest hubs for innovation in research
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationMarina Biotech Monetizes UNA Intellectual Property Estate through Agreement with Arcturus Therapeutics
Marina Biotech Monetizes UNA Intellectual Property Estate through Agreement with Arcturus Therapeutics CAMBRIDGE, MA, August 14, 2013 Marina Biotech, Inc. (OTC Pink: MRNA): Assigns Unlocked Nucleobase
More informationACHIEVING THE POTENTIAL OF GENOME EDITING. The perspective of the European Biotech Industry
ACHIEVING THE POTENTIAL OF GENOME EDITING The perspective of the European Biotech Industry JANUARY 2018 The European Union faces an opportunity to create headroom for innovation and continued investment
More informationCorporate Presentation. March 2018
Corporate Presentation March 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation
More informationEducation Critical to Stem Cell Therapy Pipeline
June 2016 Education Critical to Stem Cell Therapy Pipeline Don L. Gibbons Senior Science and Education Communication Officer ABOUT California Institute for Regenerative Medicine (CIRM) CIRM is California
More informationMedical Topics: Gene Therapy. E. Anne Jackson, FSA MAAA July 30, 2018
Medical Topics: Gene Therapy E. Anne Jackson, FSA MAAA July 30, 2018 Agenda Terminology Crash course in the science Existing FDA-approved gene therapies Underwriting implications 2 Terms related to high
More informationAdenoVerse Platform for Translational Development of Innovative Gene and Cell Therapies Cell & Gene Therapy World January 18, 2017
AdenoVerse Platform for Translational Development of Innovative Gene and Cell Therapies Cell & Gene Therapy World Douglas E. Brough, Ph.D. Chief Scientific Officer Safe Harbor Statement Statements herein
More informationCell and Gene Therapy Catapult clinical trials database
Cell and Gene Therapy Catapult clinical trials database Executive summary The number of cell and gene therapy clinical trials in the UK continues to increase with 85 ongoing trials at present, representing
More informationADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. COMMUNICATE INNOVATE EXPLORE COLLABORATE PARTNERSHIPS THAT BENEFIT YOU, US, AND ALL OF MANKIND Since Eli Lilly and Company was founded
More informationEmployment in the biopharma industry grew almost 5 percent in 2014, the last full year for which we have data. This is the highest annual growth rate
Thank you, Mr. Chairman, and members of the committee. I m Sarah MacDonald, Executive Vice President at MassBio, the life sciences trade association now representing over 700 member organizations. First,
More informationFrom regulation to reality challenges in translation of gene therapy and cell-based medicinal products
From regulation to reality challenges in translation of gene therapy and cell-based medicinal products Gene therapy case study: ADA-SCID Alessandro Aiuti Jonathan Appleby HSR-TIGET is focused on the implementation
More informationMeet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer
Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer Written by Clara Rodríguez Fernández Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing
More informationKRISANI BIO SCIENCES PVT. LTD.
KRISANI BIO SCIENCES PVT. LTD. Flat B2, 2 nd Floor, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad, Telangana 500078. Email: kkr@krisanibio.com. URL: www.krisanibio.com Contact Number: +91 98494
More informationArtificial Intelligence in Life Sciences: The Formula for Pharma Success Across the Drug Lifecycle
Volume XX, Issue 60 Artificial Intelligence in Life Sciences: The Formula for Pharma Success Across the Drug Lifecycle Artificial intelligence (AI) has the potential to transform the pharmaceutical industry.
More informationVoyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2016 UMass Center for Clinical and Translational Science Research Retreat
More informationGene Therapy Clinical Pipeline
Gene Therapy Clinical Pipeline Sector Overview Lyndsey Scull Vice President, Communications Alliance for Regenerative Medicine 2 About ARM International advocacy organization Dedicated to realizing the
More informationQ4 and Full Year 2017 Conference Call. February 22, 2018
Q4 and Full Year 2017 Conference Call February 22, 2018 Agenda Welcome McDavid Stilwell VP, Corporate Communications and Investor Relations Q4 2017 and Full Year Review and Recent Highlights Dr. Sandy
More information- OMICS IN PERSONALISED MEDICINE
SUMMARY REPORT - OMICS IN PERSONALISED MEDICINE Workshop to explore the role of -omics in the development of personalised medicine European Commission, DG Research - Brussels, 29-30 April 2010 Page 2 Summary
More informationPress Release. Interim Data Summary
Print Page Close Window Press Release bluebird bio Reports Interim Clinical Data from Starbeam Study of Lenti-D at AAN 2016 Annual Meeting First clinical data to be presented from Phase 2/3 Starbeam Study;
More informationTo Partner or Not to Partner:
To Partner or Not to Partner: Determining Your Commercialization Plan Written by: Debbi Amanti Belanger, Principal, ClearView Healthcare Partners Deciding whether to partner an important late-stage asset
More informationINUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR REGENERATIVE MEDICINE
INUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR > SOLUTIONS AND HOPE Millions of people worldwide suffer from deadly diseases, chronic conditions and congenital disorders
More informationThis presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements
More informationThe NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England
The NHS approach to personalised medicine in respiratory disease Professor Sue Hill @CSOSue Chief Scientific Officer for England Jul 2017 Genomics is probably the biggest breakthrough in the last 50 years.
More informationAcquisition of Vtesse Inc. Increased Focus on Orphan and Pediatric Diseases
Acquisition of Vtesse Inc. Increased Focus on Orphan and Pediatric Diseases 1 Forward Looking Statement This presentation contains "forward-looking statements" as that term is defined in the Private Securities
More informationABOUT GLYCOSTEM. Company Overview
ABOUT GLYCOSTEM The company is a clinical stage biotech company established in the Netherlands in 2007. The company s headquarters and new state-of-the-art lab and production facilities are based at Pivot
More informationPress Release. Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies exercises its option to acquire all shares of oncolytic virus company ViraTherapeutics ViraTherapeutics
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationBayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms
Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs
More information+ + + MALARIA HIV/AIDS TUBERCULOSIS LEISHMANIASIS CHAGAS DISEASE DENGUE EBOLA ZIKA
At the Center for Infectious Disease Research, we use systems biology approaches and cutting-edge technologies to accelerate the development of life-saving drugs, diagnostics and treatments for the world
More informationGene therapy. Findings by Alert
Gene therapy Published Mar 21, 2000 Version 1 Findings by Alert Research in gene therapy has increased dramatically during the past 15 years, particularly in the United States. The research has encompassed
More informationRXi Pharmaceuticals. BioPharm America September 26, 2017 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals BioPharm America September 26, 2017 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationGlobal Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box.
Global Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box. The purpose of this presentation Looking for Joint Venture
More informationClass XII - Biology Biotechnology and its Applications Chapter-wise Questions
Class XII - Biology Biotechnology and its Applications Chapter-wise Questions MULTIPLE-CHOICE QUESTIONS 1. Bt cotton is not: a. A GM plant b. Insect resistant c. A bacterial gene expressing system d. Resistant
More informationTrump Biotech Special: A $7 Stock with Yuge Potential. Trump Biotech Special: A $7 Stock with Yuge Potential
Trump Biotech Special: A $7 Stock with Yuge Potential Xenon Pharmaceuticals: Vastly Undervalued With Yuge Potential It seems appropriate after all but secured the Republican nomination to highlight a small
More informationBusiness Concepts for Life Scientists: Strategy
Business Concepts for Life cientists: trategy Deb Dauber, PhD, MPH Healthcare Consultant UCF Alum andy Waugh-Ruggles, PhD Founder and Innovator UCF Alum Content Contributors Michael Penn, MD, PhD Anatol
More informationExceptions for inventions involving the treatment of humans. James Love, KEI
Exceptions for inventions involving the treatment of humans James Love, KEI AIFA Workshop on CAR-T in operation: Challenges and Perspectives Rome, Italy 24 January 2019 TRIPS Article 27: Patentable Subject
More informationWhere are we with gene therapy?
Where are we with gene therapy? Session 9: Gene Based Therapies Professor Alan Boyd PFPM 7 th February 2018 Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians, UK Topics to be covered Gene
More informationChairman Cole, Ranking Member DeLauro and distinguished members of the
Fiscal Year 2019 House Appropriations Committee Subcommittee on Labor, Health and Human Services, Education and Related Agencies Appropriations Testimony Cynthia A. Bens, Senior Vice President, Public
More informationBioWorld s. PARTNER in FOCUS: Immunomic Therapeutics Inc. AN ADVERTISING SERVICE FROM BIOWORLD
BioWorld s PARTNER in FOCUS: Immunomic Therapeutics Inc. AN ADVERTISING SERVICE FROM BIOWORLD THE REMARKABLE SCIENCE BEHIND LAMP TECHNOLOGY AND ITS POTENTIAL TO TREAT HUMAN DISEASE The body s own immune
More informationMolecular Partners launches IPO on SIX Swiss Exchange
For release in Switzerland only. This is a restricted communication and you must not forward it or its contents to any person to whom forwarding it is prohibited by the legends contained therein. In particular,
More informationJUST THE FACTS 1. Nearly 300 Cell and Gene Therapies in Development for A Broad Range of Diseases
TM TM MEDICINES IN DEVELOPMENT 018 REPORT CELL AND GENE THERAPIES JUST THE FACTS 1 5 DISEASES CURRENTLY TREATED WITH CELL AND GENE THERAPY MEDICINES IN DEVELOPMENT FOR CELL THERAPY AND GENE THERAPY Nearly
More informationnot to be republished NCERT BIOTECHNOLOGY AND ITS APPLICATIONS CHAPTER BIOLOGY, EXEMPLAR PROBLEMS MULTIPLE-CHOICE QUESTIONS
82 BIOLOGY, EXEMPLAR PROBLEMS CHAPTER 12 BIOTECHNOLOGY AND ITS APPLICATIONS 1. Bt cotton is not: a. A GM plant b. Insect resistant MULTIPLE-CHOICE QUESTIONS c. A bacterial gene expressing system d. Resistant
More informationWelcome to the 2007 Annual Meeting of Stockholders
Welcome to the 2007 Annual Meeting of Stockholders Forward-Looking Statement This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform
More informationSanten Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device
Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device Akira Kurokawa President & CEO August 2, 2016 Copyright 2016 Santen Pharmaceutical Co., Ltd. All rights reserved. 1 External
More informationLA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES
LA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES Francesca Pasinelli Direttore Generale 3 Congresso Nazionale SIFaCT Roma, 9 ottobre 2015 About Telethon Fondazione Telethon is
More informationAxel Hoos, M.D., Ph.D., SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno Oncology, GSK
Magazine Article September 1, 2016 Source: Life Science Leader By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Is Oncology Back At GSK? Did It Ever Leave? Axel Hoos,
More informationAndrew Schorr: Is there anything you ve been discussing that you d like to update people about now?
News from ASH: Advances in Bleeding Disorders ASH Conference Coverage December 8, 2008 Craig Kessler, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors,
More informationWorking Together for Better Health Partnering with Boehringer Ingelheim. JOURNEE COLLABORATIVE DE LYONBIOPOLE October 10, 2017
Working Together for Better Health Partnering with Boehringer Ingelheim JOURNEE COLLABORATIVE DE LYONBIOPOLE October 10, 2017 Welcome to Partnering with Boehringer Ingelheim Our guiding principle Value
More informationGenetic tests are available for hundreds of disorders. DNA testing can pinpoint the exact genetic basis of a disorder.
Human DNA Analysis Human DNA Analysis There are roughly 6 billion base pairs in your DNA. Biologists search the human genome using sequences of DNA bases. Genetic tests are available for hundreds of disorders.
More informationTHE CRISPR-CAS9 DISPUTE
WHO OWNS THE INTELLECTUAL PROPERTY? THE CRISPR-CAS9 DISPUTE UTRF Tech Talks Dr. Lakita Cavin February 23, 2017 WHAT IS CRISPR-Cas9 Clustered Regularly-Interspaced Short Palindromic Repeats/CRISPR associated
More informationWorld Congress on Industrial Biotechnology May, 2014
World Congress on Industrial Biotechnology May, 2014 1 The Value Proposition Leader in precision gene editing RTDS Non transgenic, non GMO platform RTDS Broadly applicable across many organisms Significant
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT. For personal use only
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationPost-doctoral PharmD Fellowship Programs
Post-doctoral PharmD Fellowship Programs Table of Contents About Bioverativ Messages from Medical & Regulatory Our Pipeline Partnership with Northeastern University Global Medical Fellowship Global Regulatory
More informationA Next Generation Stem Cell Therapeutics Company. Investor Presentation: Cynata Therapeutics Limited
A Next Generation Stem Cell Therapeutics Company Investor Presentation: Cynata Therapeutics Limited Important Information This presentation has been prepared by Cynata Therapeutics Limited. ( Cynata or
More informationAbout Sarepta Therapeutics
Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene Therapy Development and Commercial Supply -- The partnership will provide commercial supply
More informationTogether, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days
Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting Together, all nine participants
More informationThe Leader in AAV Gene Therapy. A Guide to AAV Gene Therapy for MPS I and II
The Leader in AAV Gene Therapy A Guide to AAV Gene Therapy for MPS I and II REGENXBIO seeks to understand the diverse perspectives of patients, caregivers and families, and to learn from their experiences
More informationSynthetic vaccine research and development. Comprehensive and innovative synthetic biology solutions and technologies
Synthetic vaccine research and development Comprehensive and innovative synthetic biology solutions and technologies From plan to product, Thermo Fisher Scientific supports your synthetic vaccine goals
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationBayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing
News Release Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing BlueRock Therapeutics is focused on breakthrough treatments
More informationSangamo BioSciences Reports Third Quarter 2013 Financial Results
October 23, 2013 Sangamo BioSciences Reports Third Quarter 2013 Financial Results Recent Financing Enhances Cash Position RICHMOND, Calif., Oct. 23, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq:
More informationDB3230 Midterm 1 11/15/2013 Name:
1. (15 pts) Nuclear cloning by John Gurdon was rarely successful in producing fertile adults. Why not? Explain why serial transplantation improves the success rate. What else could you do to improve the
More informationConference call transcript for the March 2017 Quarterly Report
ASX ANNOUNCEMENT Conference call transcript for the March 2017 Quarterly Report Sydney Australia, 31 May 2017: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its transcript
More informationUnderstanding brain diseases from stem cells to clinical trials
Understanding brain diseases from stem cells to clinical trials Alan Mackay Sim Griffith Institute for Drug Discovery Griffith University Brisbane, QLD Making ES cells Fertilise an egg Put in a dish Embryonic
More informationGenome Editing Technology - Principle -
Effective Date: 31.10.2017 Doc ID: 20290213 Version: 1.0 Status: Approved Planned Effective Date: 31-Oct-2017 00:00 CET (Server Date) Genome Editing Technology - Principle - Rationale Genome editing is
More informationHELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY
HELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY PROVIDING COMPREHENSIVE SOLUTIONS IN A COMPLEX ENVIRONMENT PPD IS A PARTNER WITH PROVEN CAPABILITIES THAT SUPPORT AND ADVANCE ONCOLOGY RESEARCH
More informationWelcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications
Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications 1 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning
More informationProof of Concept. Achieve your molecule s full potential
Proof of Concept Achieve your molecule s full potential Table of contents 01 Maximize the value of your molecule 02 Enhance your resources and 03 Increase your speed and efficiency 04 your product s market
More informationCombination Therapies. Inhibitors
Combination Therapies with Immune The Value of Partnerships Checkpoint - Case Study - Inhibitors The Value of Partnerships - Case Study - New data is forecasting that the immune checkpoint inhibitor market
More informationGUIDE HEA
Companies are often overwhelmed by the field of digital health. From digital and med device companies to biotechnology and pharmaceutical companies, there is a struggle to cut through the noise of numerous
More informationStem Cel s Key Words:
Stem Cells Key Words: Embryonic stem cells, Adult stem cells, ips cells, self-renewal, differentiation, pluripotent, multipotent, Inner cell mass, Nuclear transfer (Therapeutic cloning), Feeder cells,
More informationHUMAN GENOME EDITING FAQs
HUMAN GENOME EDITING FAQs DEFINITIONS } What is a genome? } What is genome editing and how does it work? } What is the difference between somatic cell and germline genome editing? } What are the genome
More informationThe Impact of Translational Research
The Impact of Translational Research Chris Watkins and Ian Viney Medical Research Council October 2016 Open Council Translation Across the MRC Portfolio MRC support for translational medicine Proportion
More informationCortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14, 2015 Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia Cortendo AB (publ) [ticker: CORT
More informationPartnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC
Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives Oncology Therapeutic Area Janssen Research & Development, LLC To Our Potential Partners We offer partners the depth of
More informationStem Cell Research: Identifying emerging high priority policy issues
The state stem cell agency Stem Cell Research: Identifying emerging high priority policy issues Ellen G. Feigal, M.D. SVP, Research and Development National Cancer Policy Summit Washington, DC November
More informationUpdates to the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines)
Updates to the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) Jacqueline Corrigan-Curay, J.D. M.D. Acting Director Office of Biotechnology Activities National Institute
More informationAdoptive cellular therapies are based on the administration of live cells into a patient in order for them to serve a therapeutic purpose.
Adoptive cellular therapies are based on the administration of live cells into a patient in order for them to serve a therapeutic purpose. Pharmaceutical products have been historically made of purified
More informationE&T objectives in evolving pharma business models. Magda Chlebus Director Science Policy Brussels, 2 March 2015
E&T objectives in evolving pharma business models Magda Chlebus Director Science Policy Brussels, 2 March 2015 Education adapted to demand? Declining number of students choosing science Education still
More informationStifel Nicolaus Healthcare Conference. September 2012
Stifel Nicolaus Healthcare Conference September 212 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of
More informationCompany Report Daring to be different
Company Report 2010 Daring to be different Daring to be different Galapagos has continued to follow its own unique path and is now a leading international biotechnology company. In our 2010 report, we
More informationQ Earnings and Corporate Developments. October 31, 2018
Q3 2018 Earnings and Corporate Developments October 31, 2018 1 Intellia Therapeutics Legal Disclaimers This presentation contains forward-looking statements of Intellia Therapeutics, Inc. ( Intellia )
More informationIMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
More informationMAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE
MAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE THE RESEARCH WE DO TODAY WILL DETERMINE THE TYPE OF MEDICAL AND SURGICAL PRACTICE WE CARRY ON AT THE CLINIC
More informationFDA-Approved Gene Therapy Reverses Blindness in Children & Adults
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/fda-approved-genetherapy-reverses-blindness-in-children-adults/10127/
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationDevelopment Stage of Therapeutic Vaccines: The Regulator s View
Development Stage of Therapeutic Vaccines: The Regulator s View Thomas Hinz Head, Section Therapeutic Vaccines Paul Ehrlich Institute, Germany thomas.hinz@pei.de 1 DISCLAIMER This is the personal views
More information